Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial

Psychopharmacology

Volumn 140, Issue 2, 1998, Pages 173-184

  Keck Jr , Paul ^a   Buffenstein, Alan ^b   Ferguson, James ^c   Feighner, John ^d   Jaffe, William ^d   Harrigan, Edmund P ^e   Morrissey, Marilyn R ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b QUEEN S MEDICAL CENTER   (United States)

^c Pharmacology Research Corporation   (United States)

^d Pfizer Central Research ^*  (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Doubl e blind; Efficacy; Placebo; Schizoaffective; Schizophrenia; Tolerability; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ABDOMINAL PAIN; ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOIDISM; SCHIZOPHRENIA; WEIGHT GAIN;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES;

EID: 7844224760     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050755     Document Type: Article

References (30)

1. Allebeck P (1989) Schizophrenia: a life shortening disease. Schizophr Bull 15 : 81-89
2. Alvir JM, Lieberman JA, Safferman AZ, Schimmer JL, Schaff JA (1993) Clozapine-induced agranulocytosis. incidence and risk factors in the United States. N Engl J Med 329 : 162 167
3. Andreasen NJC (1982) Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 36 : 1325 1330
4. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised, APA, Washington, D.C.
5. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154 : 672 583
6. 11C-raclopride. Psychopharmacology 112 : 308 314
7. 2 receptors by the neuroleptic ziprasidone (CP-88,059 01) determined by positron emission tomography. Psychopharmacology 124 : 141 147
8. Chappell PB, Scahill LD, Leckman JF (1997) Future therapies of Tourette's Syndrome. Neurol Clin N Am 15 : 429 449
9. 18F]setoperone in healthy volunteers. Eur Neuropsychopharmacol 6 : 177
10. Goldstein JM (1995) Preclinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 4 : 291 298
11. Howard HR, Prakash C. Seeger TE (1994) Ziprasidone hydrochloride. Drugs Future 19 : 560 563
12. Howard HR, Lowe JA, Seeger TF, Seymour PA, Zorn SH, Maloney PR, Ewing FE, Newman ME, Schmidt AW, Furman JS, Robinson GL, Jackson E, Johnson C, Morrone J (1996) 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem 39 : 143 148
13. Janiszewski JS, Fouda HG, Cole RO (1995) Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059. with solid-phase extraction and narrow-bore high-performance liquid chromatography. J Chromatogr 668 : 133 139
14. King DJ (1998) Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8 : 33 42
15. Ko G, Golff D, Herz, L, Wilner K, Posever T, Howard H, Heym J, Wong D. Etienne P (1995) Status report : ziprasidone. Schizophr Res 15 : 154
16. Meltzer HY, Shigero M, Lee JC (1989) The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25 : 390 392
17. Metropolitan Life Insurance Company (1993) Height and weight standards. New York. NY.
18. Möller HJ (1995) The negative component in schizophrenia. Acta Psychiatr Scand 91 : 11-14
19. Möller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW, et al (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 115 : 221 228
20. National Institutes of Mental Health (1976a) Clinical Global Impression Severity Scale. In: Guy W (ed) ECDEU Assessment manual for psychopharmacology. U.S. Government Printing Office, Washington, D.C.
21. National Institutes of Mental Health (1976b) Clinical Global Impression Improvement Scale. In: Guy W (ed) ECDEU Assessment manual for psychopharmacology. U.S. Government Printing Office, Washington, D.C.
22. National Institutes of Mental Health (1976c) Abnormal movement scale. In: Guy W (ed) LCDEU Assessment manual for psychopharmacology. U.S. Government Printing Office, Washington, D.C.
23. Reeves KR. Harrigan EP (1996) The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaffective disorder. Eur Psychiatry 11 : 422S
24. Rickels K. Schweizer E. (1993) The treatment of generalized anxiety disorder in patients with depressive symptomology. J Clin Psychiatry 54 [Suppl]: 20-22
25. Roy A, Thompson R, Kennedy S (1983) Depression in chronic schizophrenia. Br J Psychiatry 142 : 465-470
26. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, Heym J (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275 : 101 113
27. Simpson GM. Angus JWS (1970) A rating scale for extrapyrami-dal side effects. Acta Psychiatr Scand 212 [Suppl]: 111 199
28. Tandon R, Harrigan E, Zorn S (1997) Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4 : 159 177
29. Woerner MG, Mannuzza S, Kane JM (1988) Anchoring the BPRS to improved reliability Psychopharmacol Bull 24 : 112 117
30. Zorn SH, Seeger TF, Seymour PA, Schmidt AW, Schulz OW, Lebel LA, McClean S, Guanowsky V, Howard HR, Lowe JA. Heym J (1995) Ziprasidone (CP-88,059): preclinical pharmacology review. Jpn J Neuropsychopharmacol 17 : 701-707